HEADER ANTIBIOTIC 06-JAN-06 2CBT TITLE CRYSTAL STRUCTURE OF THE NEOCARZINOSTATIN 4TES1 MUTANT BOUND TITLE 2 TESTOSTERONE HEMISUCCINATE. COMPND MOL_ID: 1; COMPND 2 MOLECULE: NEOCARZINOSTATIN; COMPND 3 CHAIN: A, B; COMPND 4 SYNONYM: NCS, MITOMALCIN, MMC; COMPND 5 ENGINEERED: YES; COMPND 6 MUTATION: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: STREPTOMYCES CARZINOSTATICUS; SOURCE 3 ORGANISM_TAXID: 1897; SOURCE 4 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 5 EXPRESSION_SYSTEM_TAXID: 562; SOURCE 6 EXPRESSION_SYSTEM_STRAIN: BLR(DE3)PLYSS KEYWDS ANTIBIOTIC, PHAGE-DISPLAY, HAPTEN BINDING, NEOCARZINOSTATIN, KEYWDS 2 ANTIMICROBIAL, DNA-BINDING EXPDTA X-RAY DIFFRACTION AUTHOR A.DREVELLE,M.GRAILLE,B.HEYD,I.SOREL,N.ULRYCK,F.PECORARI,M.DESMADRIL, AUTHOR 2 H.VAN TILBEURGH,P.MINARD REVDAT 4 13-DEC-23 2CBT 1 REMARK REVDAT 3 24-FEB-09 2CBT 1 VERSN REVDAT 2 26-APR-06 2CBT 1 JRNL REVDAT 1 22-MAR-06 2CBT 0 JRNL AUTH A.DREVELLE,M.GRAILLE,B.HEYD,I.SOREL,N.ULRYCK,F.PECORARI, JRNL AUTH 2 M.DESMADRIL,H.VAN TILBEURGH,P.MINARD JRNL TITL STRUCTURES OF IN VITRO EVOLVED BINDING SITES ON JRNL TITL 2 NEOCARZINOSTATIN SCAFFOLD REVEAL UNANTICIPATED EVOLUTIONARY JRNL TITL 3 PATHWAYS. JRNL REF J.MOL.BIOL. V. 358 455 2006 JRNL REFN ISSN 0022-2836 JRNL PMID 16529771 JRNL DOI 10.1016/J.JMB.2006.02.002 REMARK 1 REMARK 1 REFERENCE 1 REMARK 1 AUTH B.HEYD,F.PECORARI,B.COLLINET,E.ADJADJ,M.DESMADRIL,P.MINARD REMARK 1 TITL IN VITRO EVOLUTION OF THE BINDING SPECIFICITY OF REMARK 1 TITL 2 NEOCARZINOSTATIN, AN ENEDIYNE-BINDING CHROMOPROTEIN. REMARK 1 REF BIOCHEMISTRY V. 42 5674 2003 REMARK 1 REFN ISSN 0006-2960 REMARK 1 PMID 12741824 REMARK 1 DOI 10.1021/BI0273664 REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : SHELXL-97 REMARK 3 AUTHORS : G.M.SHELDRICK REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 20.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 COMPLETENESS FOR RANGE (%) : 98.9 REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT (NO CUTOFF). REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : 0.218 REMARK 3 FREE R VALUE (NO CUTOFF) : 0.344 REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : NULL REMARK 3 REMARK 3 FIT/AGREEMENT OF MODEL FOR DATA WITH F>4SIG(F). REMARK 3 R VALUE (WORKING + TEST SET, F>4SIG(F)) : NULL REMARK 3 R VALUE (WORKING SET, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE (F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%, F>4SIG(F)) : NULL REMARK 3 FREE R VALUE TEST SET COUNT (F>4SIG(F)) : NULL REMARK 3 TOTAL NUMBER OF REFLECTIONS (F>4SIG(F)) : 9000 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1578 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 56 REMARK 3 SOLVENT ATOMS : 30 REMARK 3 REMARK 3 MODEL REFINEMENT. REMARK 3 OCCUPANCY SUM OF NON-HYDROGEN ATOMS : NULL REMARK 3 OCCUPANCY SUM OF HYDROGEN ATOMS : NULL REMARK 3 NUMBER OF DISCRETELY DISORDERED RESIDUES : NULL REMARK 3 NUMBER OF LEAST-SQUARES PARAMETERS : NULL REMARK 3 NUMBER OF RESTRAINTS : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM RESTRAINT TARGET VALUES. REMARK 3 BOND LENGTHS (A) : 0.008 REMARK 3 ANGLE DISTANCES (A) : 1.508 REMARK 3 SIMILAR DISTANCES (NO TARGET VALUES) (A) : NULL REMARK 3 DISTANCES FROM RESTRAINT PLANES (A) : NULL REMARK 3 ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 NON-ZERO CHIRAL VOLUMES (A**3) : NULL REMARK 3 ANTI-BUMPING DISTANCE RESTRAINTS (A) : NULL REMARK 3 RIGID-BOND ADP COMPONENTS (A**2) : NULL REMARK 3 SIMILAR ADP COMPONENTS (A**2) : NULL REMARK 3 APPROXIMATELY ISOTROPIC ADPS (A**2) : NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED: NULL REMARK 3 REMARK 3 STEREOCHEMISTRY TARGET VALUES : NULL REMARK 3 SPECIAL CASE: NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: TWINNING FRACTION 0.42 REMARK 4 REMARK 4 2CBT COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 06-JAN-06. REMARK 100 THE DEPOSITION ID IS D_1290027096. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : 100.0 REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : ESRF REMARK 200 BEAMLINE : BM14 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.987 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC CCD REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO REMARK 200 DATA SCALING SOFTWARE : SCALEPACK REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 9943 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.200 REMARK 200 RESOLUTION RANGE LOW (A) : 20.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 2.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.9 REMARK 200 DATA REDUNDANCY : 11.00 REMARK 200 R MERGE (I) : 0.06000 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 18.3000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.26 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.9 REMARK 200 DATA REDUNDANCY IN SHELL : 11.00 REMARK 200 R MERGE FOR SHELL (I) : 0.46000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 2.900 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1NCO REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 43.71 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.20 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 0.9 M SODIUM CITRATE, 0.1 M HEPES PH REMARK 280 7.5 AND 3% ETHANOL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 65 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+2/3 REMARK 290 3555 -X+Y,-X,Z+1/3 REMARK 290 4555 -X,-Y,Z+1/2 REMARK 290 5555 Y,-X+Y,Z+1/6 REMARK 290 6555 X-Y,X,Z+5/6 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 85.94000 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 42.97000 REMARK 290 SMTRY1 4 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 64.45500 REMARK 290 SMTRY1 5 0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 5 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 21.48500 REMARK 290 SMTRY1 6 0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 107.42500 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PQS REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 400 REMARK 400 COMPOUND REMARK 400 ENGINEERED RESIDUE IN CHAIN A, ASP 67 TO TRP REMARK 400 ENGINEERED RESIDUE IN CHAIN A, GLY 69 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN A, CYS 71 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN A, LEU 79 TO TYR REMARK 400 ENGINEERED RESIDUE IN CHAIN A, CYS 81 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN A, PHE 86 TO ILE REMARK 400 ENGINEERED RESIDUE IN CHAIN A, PHE 112 TO TRP REMARK 400 ENGINEERED RESIDUE IN CHAIN A, GLN 128 TO HIS REMARK 400 ENGINEERED RESIDUE IN CHAIN A, GLY 130 TO THR REMARK 400 ENGINEERED RESIDUE IN CHAIN A, SER 132 TO ARG REMARK 400 ENGINEERED RESIDUE IN CHAIN A, ALA 135 TO LEU REMARK 400 ENGINEERED RESIDUE IN CHAIN A, GLY 136 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN B, ASP 67 TO TRP REMARK 400 ENGINEERED RESIDUE IN CHAIN B, GLY 69 TO ALA REMARK 400 ENGINEERED RESIDUE IN CHAIN B, CYS 71 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN B, LEU 79 TO TYR REMARK 400 ENGINEERED RESIDUE IN CHAIN B, CYS 81 TO SER REMARK 400 ENGINEERED RESIDUE IN CHAIN B, PHE 86 TO ILE REMARK 400 ENGINEERED RESIDUE IN CHAIN B, PHE 112 TO TRP REMARK 400 ENGINEERED RESIDUE IN CHAIN B, GLN 128 TO HIS REMARK 400 ENGINEERED RESIDUE IN CHAIN B, GLY 130 TO THR REMARK 400 ENGINEERED RESIDUE IN CHAIN B, SER 132 TO ARG REMARK 400 ENGINEERED RESIDUE IN CHAIN B, ALA 135 TO LEU REMARK 400 ENGINEERED RESIDUE IN CHAIN B, GLY 136 TO SER REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 ALA A 1001 REMARK 465 ALA B 2001 REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 OH TYR A 1045 NE2 HIS A 1094 1.73 REMARK 500 OH TYR A 1045 CE1 HIS A 1094 1.90 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A1014 -164.75 -161.04 REMARK 500 ALA A1028 126.38 -38.12 REMARK 500 TRP A1039 84.65 -47.48 REMARK 500 ILE A1052 170.38 -59.83 REMARK 500 ASP A1058 -163.86 -71.24 REMARK 500 ASN A1060 41.52 -97.01 REMARK 500 ALA A1063 -166.42 -164.35 REMARK 500 THR A1085 132.37 -33.97 REMARK 500 ASP A1087 163.78 50.71 REMARK 500 CYS A1088 4.02 -154.51 REMARK 500 THR A1089 -7.52 138.89 REMARK 500 THR A1090 -97.01 -66.58 REMARK 500 SER A1102 -16.34 77.85 REMARK 500 PRO A1105 -162.77 -79.74 REMARK 500 THR B2008 116.95 -166.63 REMARK 500 SER B2014 -156.81 -134.12 REMARK 500 ALA B2024 139.29 177.69 REMARK 500 TRP B2039 87.06 -66.32 REMARK 500 ASP B2058 -152.94 -57.91 REMARK 500 ASN B2060 47.46 -102.69 REMARK 500 ALA B2063 165.32 158.96 REMARK 500 ARG B2082 94.18 -69.52 REMARK 500 ASP B2087 175.75 43.12 REMARK 500 CYS B2088 -2.11 -167.13 REMARK 500 THR B2089 29.46 131.37 REMARK 500 ALA B2100 -6.82 -55.82 REMARK 500 SER B2102 -15.86 78.38 REMARK 500 SER B2111 142.95 -173.83 REMARK 500 REMARK 500 REMARK: NULL REMARK 700 REMARK 700 SHEET REMARK 700 THE SHEET STRUCTURE OF THIS MOLECULE IS BIFURCATED. IN REMARK 700 ORDER TO REPRESENT THIS FEATURE IN THE SHEET RECORDS BELOW, REMARK 700 TWO SHEETS ARE DEFINED. REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE TH2 A1120 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE TH2 B2120 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 1J5H RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF APO-NEOCARZINOSTATIN REMARK 900 RELATED ID: 1J5I RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF A NOVEL CHROMOPROTEIN DERIVED FROMAPO- REMARK 900 NEOCARZINOSTATIN AND A SYNTHETIC CHROMOPHORE REMARK 900 RELATED ID: 1KVH RELATED DB: PDB REMARK 900 NCSI-GB-BULGE-DNA COMPLEX INDUCED FORMATION OF A DNA BULGESTRUCTURE REMARK 900 BY A MOLECULAR WEDGE LIGAND-POST-ACTIVATEDNEOCARZINOSTATIN REMARK 900 CHROMOPHORE REMARK 900 RELATED ID: 1MP7 RELATED DB: PDB REMARK 900 A THIRD COMPLEX OF POST-ACTIVATED NEOCARZINOSTATINCHROMOPHORE WITH REMARK 900 DNA. BULGE DNA BINDING FROM THE MINORGROOVE REMARK 900 RELATED ID: 1NCO RELATED DB: PDB REMARK 900 HOLO-NEOCARZINOSTATIN (CONTAINING CHROMOPHORE) COMPLEX WITH APO- REMARK 900 CARZINOSTATIN (CONTAINING MPD) REMARK 900 RELATED ID: 1NOA RELATED DB: PDB REMARK 900 NEOCARZINOSTATIN REMARK 900 RELATED ID: 1O5P RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF HOLO-NEOCARZINOSTATIN REMARK 900 RELATED ID: 2CBM RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE APO-FORM OF A NEOCARZINOSTATIN MUTANT REMARK 900 EVOLVED TO BIND TESTOSTERONE. REMARK 900 RELATED ID: 2CBO RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE NEOCARZINOSTATIN 3TES24 MUTANT BOUND TO REMARK 900 TESTOSTERONE HEMISUCCINATE. REMARK 900 RELATED ID: 2CBQ RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE NEOCARZINOSTATIN 1TES15 MUTANT BOUND TO REMARK 900 TESTOSTERONE HEMISUCCINATE. DBREF 2CBT A 1001 1112 UNP P0A3R9 NCZS_STRCZ 35 146 DBREF 2CBT B 2001 2112 UNP P0A3R9 NCZS_STRCZ 35 146 SEQADV 2CBT TRP A 1033 UNP P0A3R9 ASP 67 ENGINEERED MUTATION SEQADV 2CBT ALA A 1035 UNP P0A3R9 GLY 69 ENGINEERED MUTATION SEQADV 2CBT SER A 1037 UNP P0A3R9 CYS 71 ENGINEERED MUTATION SEQADV 2CBT TYR A 1045 UNP P0A3R9 LEU 79 ENGINEERED MUTATION SEQADV 2CBT SER A 1047 UNP P0A3R9 CYS 81 ENGINEERED MUTATION SEQADV 2CBT ILE A 1052 UNP P0A3R9 PHE 86 ENGINEERED MUTATION SEQADV 2CBT TRP A 1078 UNP P0A3R9 PHE 112 ENGINEERED MUTATION SEQADV 2CBT HIS A 1094 UNP P0A3R9 GLN 128 ENGINEERED MUTATION SEQADV 2CBT THR A 1096 UNP P0A3R9 GLY 130 ENGINEERED MUTATION SEQADV 2CBT ARG A 1098 UNP P0A3R9 SER 132 ENGINEERED MUTATION SEQADV 2CBT LEU A 1101 UNP P0A3R9 ALA 135 ENGINEERED MUTATION SEQADV 2CBT SER A 1102 UNP P0A3R9 GLY 136 ENGINEERED MUTATION SEQADV 2CBT TRP B 2033 UNP P0A3R9 ASP 67 ENGINEERED MUTATION SEQADV 2CBT ALA B 2035 UNP P0A3R9 GLY 69 ENGINEERED MUTATION SEQADV 2CBT SER B 2037 UNP P0A3R9 CYS 71 ENGINEERED MUTATION SEQADV 2CBT TYR B 2045 UNP P0A3R9 LEU 79 ENGINEERED MUTATION SEQADV 2CBT SER B 2047 UNP P0A3R9 CYS 81 ENGINEERED MUTATION SEQADV 2CBT ILE B 2052 UNP P0A3R9 PHE 86 ENGINEERED MUTATION SEQADV 2CBT TRP B 2078 UNP P0A3R9 PHE 112 ENGINEERED MUTATION SEQADV 2CBT HIS B 2094 UNP P0A3R9 GLN 128 ENGINEERED MUTATION SEQADV 2CBT THR B 2096 UNP P0A3R9 GLY 130 ENGINEERED MUTATION SEQADV 2CBT ARG B 2098 UNP P0A3R9 SER 132 ENGINEERED MUTATION SEQADV 2CBT LEU B 2101 UNP P0A3R9 ALA 135 ENGINEERED MUTATION SEQADV 2CBT SER B 2102 UNP P0A3R9 GLY 136 ENGINEERED MUTATION SEQRES 1 A 112 ALA ALA PRO THR ALA THR VAL THR PRO SER SER GLY LEU SEQRES 2 A 112 SER ASP GLY THR VAL VAL LYS VAL ALA GLY ALA GLY LEU SEQRES 3 A 112 GLN ALA GLY THR ALA TYR TRP VAL ALA GLN SER ALA TRP SEQRES 4 A 112 VAL ASP THR GLY VAL TYR ALA SER ASN PRO ALA ASP ILE SEQRES 5 A 112 SER SER VAL THR ALA ASP ALA ASN GLY SER ALA SER THR SEQRES 6 A 112 SER LEU THR VAL ARG ARG SER PHE GLU GLY PHE LEU TRP SEQRES 7 A 112 ASP GLY THR ARG TRP GLY THR VAL ASP CYS THR THR ALA SEQRES 8 A 112 ALA CYS HIS VAL THR LEU ARG ASP ALA LEU SER ASN GLY SEQRES 9 A 112 PRO GLU GLY VAL ALA ILE SER PHE SEQRES 1 B 112 ALA ALA PRO THR ALA THR VAL THR PRO SER SER GLY LEU SEQRES 2 B 112 SER ASP GLY THR VAL VAL LYS VAL ALA GLY ALA GLY LEU SEQRES 3 B 112 GLN ALA GLY THR ALA TYR TRP VAL ALA GLN SER ALA TRP SEQRES 4 B 112 VAL ASP THR GLY VAL TYR ALA SER ASN PRO ALA ASP ILE SEQRES 5 B 112 SER SER VAL THR ALA ASP ALA ASN GLY SER ALA SER THR SEQRES 6 B 112 SER LEU THR VAL ARG ARG SER PHE GLU GLY PHE LEU TRP SEQRES 7 B 112 ASP GLY THR ARG TRP GLY THR VAL ASP CYS THR THR ALA SEQRES 8 B 112 ALA CYS HIS VAL THR LEU ARG ASP ALA LEU SER ASN GLY SEQRES 9 B 112 PRO GLU GLY VAL ALA ILE SER PHE HET TH2 A1120 28 HET TH2 B2120 28 HETNAM TH2 TESTOSTERONE HEMISUCCINATE HETSYN TH2 4-OXO-4-{[(8ALPHA,9BETA,10ALPHA,13ALPHA,14BETA, HETSYN 2 TH2 17ALPHA)-3-OXOANDROST-4-EN-17-YL]OXY}BUTANOIC ACID FORMUL 3 TH2 2(C23 H32 O5) FORMUL 5 HOH *30(H2 O) HELIX 1 1 PRO A 1049 ILE A 1052 5 4 SHEET 1 AA 3 THR A1004 THR A1006 0 SHEET 2 AA 3 VAL A1018 ALA A1024 -1 O ALA A1022 N THR A1006 SHEET 3 AA 3 ALA A1063 THR A1068 -1 O ALA A1063 N GLY A1023 SHEET 1 AB 4 SER A1053 THR A1056 0 SHEET 2 AB 4 ALA A1031 ASP A1041 -1 O TYR A1032 N VAL A1055 SHEET 3 AB 4 HIS A1094 ARG A1098 -1 O HIS A1094 N SER A1037 SHEET 4 AB 4 VAL A1108 ALA A1109 -1 O VAL A1108 N VAL A1095 SHEET 1 AC 5 SER A1053 THR A1056 0 SHEET 2 AC 5 ALA A1031 ASP A1041 -1 O TYR A1032 N VAL A1055 SHEET 3 AC 5 VAL A1044 SER A1047 -1 O VAL A1044 N ASP A1041 SHEET 4 AC 5 PHE A1073 LEU A1077 -1 O PHE A1076 N SER A1047 SHEET 5 AC 5 ARG A1082 VAL A1086 -1 O GLY A1084 N GLY A1075 SHEET 1 BA 3 THR B2004 THR B2006 0 SHEET 2 BA 3 THR B2017 ALA B2024 -1 O ALA B2022 N THR B2006 SHEET 3 BA 3 SER B2064 VAL B2069 -1 O THR B2065 N VAL B2021 SHEET 1 BB 4 SER B2053 THR B2056 0 SHEET 2 BB 4 ALA B2031 ALA B2038 -1 O TYR B2032 N VAL B2055 SHEET 3 BB 4 CYS B2093 ARG B2098 -1 O HIS B2094 N SER B2037 SHEET 4 BB 4 VAL B2108 ALA B2109 -1 O VAL B2108 N VAL B2095 SHEET 1 BC 5 SER B2053 THR B2056 0 SHEET 2 BC 5 ALA B2031 ALA B2038 -1 O TYR B2032 N VAL B2055 SHEET 3 BC 5 ALA B2046 SER B2047 -1 O ALA B2046 N ALA B2038 SHEET 4 BC 5 PHE B2073 LEU B2077 -1 O PHE B2076 N SER B2047 SHEET 5 BC 5 GLY B2084 VAL B2086 -1 O GLY B2084 N GLY B2075 CISPEP 1 THR A 1008 PRO A 1009 0 -5.89 CISPEP 2 THR B 2008 PRO B 2009 0 -0.26 SITE 1 AC1 12 TRP A1033 SER A1047 PRO A1049 TRP A1078 SITE 2 AC1 12 ARG A1098 ASP A1099 ALA A1100 LEU A1101 SITE 3 AC1 12 SER A1102 SER B2011 TRP B2033 TH2 B2120 SITE 1 AC2 8 TRP A1033 TH2 A1120 TRP B2033 SER B2047 SITE 2 AC2 8 PRO B2049 TRP B2078 ALA B2100 SER B2102 CRYST1 52.510 52.510 128.910 90.00 90.00 120.00 P 65 12 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.019044 0.010995 0.000000 0.00000 SCALE2 0.000000 0.021990 0.000000 0.00000 SCALE3 0.000000 0.000000 0.007757 0.00000